Long‐term remission with eculizumab in atypical haemolytic uraemic syndrome. (February 2017)

• Record Type: Journal Article
• Authors: Carter, Simon; Hewitt, Ian; Kausman, Joshua
• Is Part Of: Nephrology. Volume 22(2017)Supplement 1
• Page Start: 7
• Page End: 10
• Publication Date: 2017-02
• Subjects: atypical haemolytic uraemic syndrome -- eculizumab -- long term outcome -- paediatric -- safety profile; Nephrology -- Periodicals; Kidneys -- Diseases -- Periodicals; Nephrologists -- Periodicals; 616.61; 616.61
• DOI: 10.1111/nep.12932
• Languages: English
• ISSNs: 1320-5358

Abstract

Abstract: The understanding of the role of complement dysregulation in atypical haemolytic uraemic syndrome (aHUS) has led to major changes in therapeutic approaches and outcomes. Eculizumab is a humanized anti‐C5 monoclonal antibody that inhibits the terminal complement pathway and has revolutionized the treatment and prognosis of aHUS. However, published reports to date have had relatively short‐term follow‐up. We report two paediatric cases of aHUS successfully treated with eculizumab longer than 6 years with no serious adverse events and preservation of renal function.